Clinical trials: Anti-Retroviral Agents
HIV Infections
Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to treat HIV-infected patients with indinavir (IDV) plus nelfinavir (NFV), 2 anti-HIV medications.
- Trial name
- NCT00002375
- Testing
- Indinavir sulfate, Nelfinavir mesylate
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia, HIV Infections
Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)
In HIV hypercholesterolemic patients treated with protease inhibitors, some drugs of the statin group are used to control cholesterol level.
- Trial name
- NCT00117494
- Testing
- Pravastatin, Rosuvastatin
- Where
- France
- Volunteers
- 86 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy
The purpose of this study was to evaluate the safety and antiviral activity to promote clearance of HIV-1 infected cells of VRC01 in infants with HIV beginning combination antiretroviral therapy (cART).
- Trial name
- NCT03208231
- Testing
- VRC01, Combination Antiretroviral Therapy (cART)
- Where
- 7 sites in Botswana, Brazil and 2 more
- Volunteers
- 61 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
To determine the proportion of patients treated with amprenavir, zidovudine (ZDV), stavudine (D4T) and lamivudine (3TC) whose HIV-1 RNA level remains below the level of detection during 96 weeks of therapy.
- Trial name
- NCT00001095
- Testing
- Indinavir sulfate, Amprenavir, Nevirapine
- Where
- 12 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Tuberculosis
Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam
The overall aim of the project is to evaluate rifabutin (RBT) as a replacement for rifampicin (RMP), for the combined treatment of tuberculosis and HIV infection.
- Trial name
- NCT00651066
- Testing
- rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1, rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2
- Where
- Vietnam
- Volunteers
- 47 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring
The purpose of this study is to assess the pharmacokinetics of the combination dapivirine and maraviroc vaginal ring and determine whether it is safe when used continuously for 28 days by healthy women in the United States.
- Trial name
- NCT01363037
- Testing
- Dapivirine Vaginal Ring, Maraviroc Vaginal Ring, Dapivirine-Maraviroc Vaginal Ring
- Where
- 3 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections
Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial
Highly active antiretroviral therapy (HAART) in HIV-positive patients is associated with the development of dyslipidemia, a risk factor for cardiovascular events.
- Trial name
- NCT00429845
- Testing
- Nutritional
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
HIV Testing Rate, Acceptance of Immediate ART
Thai MSM/TG Test and Treat Study
Objectives 1. To determine the uptake of universal HIV testing among Thai men who have sex with men (MSM) and transgender women (TG) 2.
- Trial name
- NCT01869595
- Where
- Thailand
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Thai Red Cross AIDS Research Centre
Healthy, HIV Infection
Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs
This 2-part study will test the safety and anti-HIV activity of capravirine alone, and the safety, anti-HIV activity, and drug interactions of capravirine combined with other anti-HIV drugs.
- Trial name
- NCT00005673
- Testing
- Capravirine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Antiretroviral Treatment Outcomes
Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression
The HIV/AIDS pandemic remains among the investigators greatest public health challenges. In the absence of an effective vaccine, focus has shifted to other prevention strategies such as pre-exposure prophylaxis.
- Trial name
- TOAST (NCT01387022)
- Testing
- Tenofovir, lamivudine and efavirenz
- Where
- South Africa
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
HIV Infections, HIV Positive
Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
The purpose of this study is to find out if antiretroviral drugs are safe and well tolerated by HIV-positive pregnant women and their infants in South Africa and Zambia.
- Conditions
- HIV Infections, HIV Positive, Pregnant Women
- Trial name
- MEPProject (NCT00639145)
- Where
- 2 sites in South Africa, Zambia
- Volunteers
- 600 people
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
HIV Infections
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
To evaluate the safety of single and multiple doses (28 daily doses) of 9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy]phosphinoyl]methoxy]propyl]adenine fumarate (PMPA) prodrug administered orally to HIV-infected patients.
- Trial name
- NCT00002396
- Testing
- Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
HIV
Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus
In this study, investigators propose to randomize 165 human immunodeficiency virus positive patients to one of three 16-week treatment conditions: (1) standard care; (2) standard care + cell phone-based adherence reminders; or…
- Trial name
- NCT01760759
- Testing
- cell phone reminders, contingency management for adherence
- Where
- 2 sites in United States
- Volunteers
- 104 people
- Sponsor
- UConn Health
HIV
Tenofovir Abacavir Platelet Activation Study
Some but not all observational studies have found that current exposure to abacavir is associated with increased risk of cardiovascular events such as myocardial infarction, stroke and cardiovascular death.
- Trial name
- TAPAS (NCT02093585)
- Testing
- abacavir (600 mg QD), tenofovir (245 mg QD)
- Where
- Denmark
- Volunteers
- 43 people
- Sponsor
- Jan Gerstoft
HAART Non-Adherence, HIV
Cell Phone Reminders Intervention
This study will use a longitudinal, experimental design. Participants will be randomized to either the intervention or the control group.
- Conditions
- HAART Non-Adherence, HIV, HIV Infections
- Trial name
- NCT01049568
- Testing
- Cell Phone Intervention
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of North Carolina, Chapel Hill
Kwashiorkor, Marasmus
Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV
It is unclear whether children with HIV and severe acute malnutrition can be started on highly active antiretroviral therapy (HAART) safely while they are still malnourished and the manner in which this therapy should start.
- Conditions
- Kwashiorkor, Marasmus, Severe Acute Malnutrition, HIV
- Trial name
- ARMAM (NCT01529125)
- Testing
- zidovudine, lamivudine, nevirapine
- Where
- Malawi
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Reproductive Health
RH and Adolescents
This study will create a model of reproductive health services for HIV-positive female adolescents in Asia.
- Trial name
- NCT02713750
- Testing
- reversible contraceptive methods
- Where
- 4 sites in Thailand
- Volunteers
- 77 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Infection, Human Immunodeficiency Virus I, HIV Infection
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
This study will assess the efficacy of subsequent protease inhibitor (PI)-containing therapy in subjects who have acquired HIV-1 protease mutations whilst receiving a GW433908 (fosamprenavir)-containing regimen.
- Trial name
- NCT00242840
- Testing
- No intervention; Observational study
- Where
- 7 sites in United States, Italy
- Volunteers
- 20 people
- Sponsor
- ViiV Healthcare
HIV Infections
The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients
To determine the safety and tolerability of hydroxyurea at two doses alone and in combination with didanosine (ddI). To compare the short term antiviral effect of ddI monotherapy versus hydroxyurea plus ddI, as measured by plasma…
- Trial name
- NCT00001074
- Testing
- Hydroxyurea, Didanosine
- Where
- 18 sites in United States
- Volunteers
- 140 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, STI
Expanded PrEP Implementation in Communities in NSW
A new NSW Ministry of Health HIV Strategy released on 1 December 2015 aims for the virtual elimination of HIV transmission in NSW by 2020.
- Trial name
- EPIC-NSW (NCT02870790)
- Testing
- TDF/FTC
- Where
- 31 sites in Australia
- Volunteers
- 9,733 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.